Research Progress of Paeonol in the Treatment of Respiratory Diseases

Abstract

Paeonol is a natural phenolic compound found in plants of the Ranunculaceae family, such as Mudanpi (Moutan Cortex) and Shaoyao (Paeoniae Radix). It possesses a wide range of pharmacological activities. Modern research confirms that paeonol exhibits various pharmacological effects, including anti-inflammatory, antioxidant, antitumor, and immunomodulatory activities, demonstrating unique application value in the treatment of respiratory diseases. With the recent development of nanodelivery systems and derivatives, issues such as low oral bioavailability, poor stability, and short half-life of paeonol have been significantly improved. This article systematically reviews the role and mechanisms of paeonol in treating respiratory diseases such as asthma, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), lung cancer, allergic rhinitis, and pneumonia, analyzing existing application problems and potential solutions, aiming to provide a theoretical basis for its clinical application and further research and development.

Keywords

paeonol - respiratory diseases - review - pharmacological activity - Mudanpi (Moutan Cortex) - Shaoyao (Paeoniae Radix)

CRediT Authorship Contribution Statement

Yuwei Song: Writing—original draft, and investigation. Xixi Wang: Investigation. Bofei Yang: Investigation. Yanqin Qin: Conceptualization, writing—review and editing, and funding acquisition. Liu Yang: Writing—review and editing.

Publikationsverlauf

Eingereicht: 02. Juni 2025

Angenommen: 24. Juli 2025

Artikel online veröffentlicht:
30. Dezember 2025

• References

• 1 Emran TB, Eva TA, Zehravi M. et al. Polyphenols as therapeutics in respiratory diseases: moving from preclinical evidence to potential clinical applications. Int J Biol Sci 2024; 20 (08) 3236-3256
• 2 GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025; 406 (10513): 1811-1872
• 3 Hu JY, Long JH, Bu XN. Trends in global and Chinese burden of chronic respiratory diseases from 1990 to 2021: Prediction and influencing factors. Zhongguo Laonianxue Zazhi 2025; 45 (18) 4435-4440
• 4 Ma Q, Cheng G, Song S. Quality differences in traditional decoction of Cynanchum paniculatum and its formula granules based on quantitative and multi- component qualitative analysis of paeonol. Zhongguo Yiyuan Yaoxue Zazhi 2025; 1-8 . Accessed November 20, 2025 at: https://link.cnki.net/urlid/42.1204.R.20250915.1456.006
• 5 Zhou F, Niu ZW, Liu Q. et al. Development of HPLC fingerprint and evaluation of antioxidant activity in moutan cortex extracts processed by different drying methods. World Chin Med 2025; 20 (03) 393-398
• 6 Ma MM, Guan XT, Sun SL. Research progress and quality marker prediction of the classical formula Liuwei Dihuang Pill. Chin J Exp Tradit Med Formul 2025: 1-19 . Accessed November 20, 2025 at: https://doi.org/10.13422/j.cnki.syfjx.20252195
• 7 Zhang H, Ge C, Fisher D. et al. Antiviral treatment for viral pneumonia: current drugs and natural compounds. Virol J 2025; 22 (01) 62
• 8 Liu J, Li X, Bai H. et al. Traditional uses, phytochemistry, pharmacology, and pharmacokinetics of the root bark of Paeonia x suffruticosa Andrews: A comprehensive review. J Ethnopharmacol 2023; 308: 116279
• 9 Liu W, Gong Z, Zhang K. et al. Paeonol protects renal tubular cells against cadmium-induced cytotoxicity via alleviating oxidative stress, inhibiting inflammatory responses and restoring autophagy. J Inorg Biochem 2022; 230: 111733
• 10 Chen YC, Chen JH, Tsai CF. et al. Protective effects of paeonol against cognitive impairment in lung diseases. J Pharmacol Sci 2024; 155 (03) 101-112
• 11 Li C, Jia WW, Yang JL, Cheng C, Olaleye OE. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. Acta Pharmacol Sin 2022; 43 (12) 3080-3095
• 12 Luo L, Zhou J, Liu X. et al. Development of modern Chinese medicine guided by molecular compatibility theory. J Adv Res 2025; 73: 713-728
• 13 Yu ZY, Chen W, Leng L. et al. Application of the gene-encoded natural diversity components repository (GNDC) in traditional Chinese medicine research. Yao Xue Xue Bao 2025; 1-25
• 14 Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. International Natural Product Sciences Taskforce. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021; 20 (03) 200-216
• 15 Wang X, Ma XY, Yu SY. et al. Research progress on the anti-pneumonia mechanisms of natural products with bioactive compounds. Fine Chem 2025: 1-16 . Accessed November 20, 2025 at: https://doi.org/10.13550/j.jxhg.20250230
• 16 Liang Y, Dong L, Yan J. et al. Paeonol attenuates atherosclerosis by regulating vascular smooth muscle cells apoptosis and modulating immune cells infiltration through reducing LTβR expression. Phytomedicine 2024; 135: 156196
• 17 Xue Y, Hu Z, Jiang Y. et al. Ultrasound-assisted deep eutectic solvent of neuroprotective extracts from Paeonia lactiflora Pall. root: Process optimization, compositions characterization, and neuroprotective activity validation. Ultrason Sonochem 2025; 120: 107449
• 18 Zhou X, Xia W, Zhang Y. et al. Cynanchum paniculatum (Bunge) Kitag. ex H. Hara: A review of its ethnopharmacology, phytochemistry and pharmacology. J Ethnopharmacol 2020; 260: 112994
• 19 Fang W, Song Q, Luo H, Wang R, Fang C. Quality evaluation of the traditional Chinese medicine moutan cortex based on UPLC fingerprinting and chemometrics analysis. Metabolites 2025; 15 (04) 281
• 20 Choy KW, Murugan D, Mustafa MR. Natural products targeting ER stress pathway for the treatment of cardiovascular diseases. Pharmacol Res 2018; 132: 119-129
• 21 Zhang XX, Shi QQ, Ji D, Niu LX, Zhang YL. Determination of the phenolic content, profile, and antioxidant activity of seeds from nine tree peony (Paeonia section Moutan DC.) species native to China. Food Res Int 2017; 97: 141-148
• 22 Gyawali A, Krol S, Kang YS. Involvement of a novel organic cation transporter in paeonol transport across the blood-brain barrier. Biomol Ther (Seoul) 2019; 27 (03) 290-301
• 23 Duan H, Zhang Q, Liu J. et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res 2021; 168: 105599
• 24 Lin S, Cui T, Jiang Y. et al. Microenvironment-responsive NIR-IIb multifunctional nanozyme platform for bacterial imaging and specialized anti-anaerobic bacteria periodontal therapy. J Nanobiotechnology 2025; 23 (01) 189
• 25 Wang HM, Cai XW, Xu M. et al. Effects of paeonol on periodontal status in elderly patients. Chin J Geriatr Dent 2019; 17 (03) 158-162
• 26 Yang J, Wang H, Li B. et al. Inhibition of ACSS2 triggers glycolysis inhibition and nuclear translocation to activate SIRT1/ATG5/ATG2B deacetylation axis, promoting autophagy and reducing malignancy and chemoresistance in ovarian cancer. Metabolism 2025; 162: 156041
• 27 Jing X, Han J, Zhang J. et al. Long non-coding RNA MEG3 promotes cisplatin-induced nephrotoxicity through regulating AKT/TSC/mTOR-mediated autophagy. Int J Biol Sci 2021; 17 (14) 3968-3980
• 28 Bihlet AR, Byrjalsen I, Andersen JR. et al. The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial. Osteoarthritis Cartilage 2024; 32 (07) 952-962
• 29 Li SS, Li GF, Liu L. et al. Evaluation of paeonol skin-target delivery from its microsponge formulation: in vitro skin permeation and in vivo microdialysis. PLoS One 2013; 8 (11) e79881
• 30 Hu X, Ding L, Cao S. et al. Pharmacokinetics, tissue distribution and excretion of paeonol and its major metabolites in rats provide a further insight into paeonol effectiveness. Front Pharmacol 2020; 11: 190
• 31 Adki KM, Murugesan S, Kulkarni YA. In silico and in vivo toxicological evaluation of paeonol. Chem Biodivers 2020; 17 (10) e2000422
• 32 Rochester CL, Alison JA, Carlin B. et al. Pulmonary rehabilitation for adults with chronic respiratory disease: An official American Thoracic Society Clinical Practice guideline. Am J Respir Crit Care Med 2023; 208 (04) e7-e26
• 33 Yang X, Niu H, Jiang W, Yu W, Jiang W. Application of pharmaceutical nanotechnologies for Chinese herbal medicines in the treatment of pulmonary diseases and lung cancer. Int J Nanomedicine 2025; 20: 10567-10593
• 34 Polverino F, Sin DD. The developmental origins of asthma and COPD. Annu Rev Physiol 2025; 1-23
• 35 Huang NX, Liu LJ, Zhao SQ. et al. Analysis of factors affecting small airway dysfunction and evaluation of cardiopulmonary function in patients with chronic duration of asthma. Zhongguo Huxi Yu Weizhong Jianhu Zazhi 2025; 24 (07) 473-480
• 36 Li K, Cao Z, Sun J. et al. Magnoliae Officinalis Cortex volatile oil alleviated asthma via dual cAMP-mediated Pathways: Anti-inflammation and bronchodilation. J Ethnopharmacol 2025; 17 (09) 355 :120622
• 37 Gan JL, Zhang JC. Changes of interleukin-33 in patients with different severities of bronchial asthma and its dose-response relationship with airway remodeling. Chongqing Yike Daxue Xuebao 2025; 1-8
• 38 Li JY, Huang HX, Li J. et al. Virtual screening of anti-airway inflammatory components in Asari Radix et Rhizoma based on 3D-QSAR, molecular docking, and experimental validation. Zhonghua Zhongyiyao Xuekan 2025; 1-20 . Accessed November 20, 2025 at https://link.cnki.net/urlid/21.1546.R.20250718.1105.004
• 39 Tang Y, Huang W, Song Q, Zheng X, He R, Liu J. Paeonol ameliorates ovalbumin-induced asthma through the inhibition of TLR4/NF-κB and MAPK signaling. Evid Based Complement Alternat Med 2018; 2018: 3063145
• 40 Du Q, Feng GZ, Shen L, Cui J, Cai JK. Paeonol attenuates airway inflammation and hyperresponsiveness in a murine model of ovalbumin-induced asthma. Can J Physiol Pharmacol 2010; 88 (10) 1010-1016
• 41 Watanabe N, Yoshida M, Hirano Y. et al. Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of IPF. Eur Respir J 2025; 66 (04) 2500022
• 42 Wagner DE, Alsafadi HN, Mitash N. et al. Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. Nat Commun 2025; 16 (01) 7099
• 43 Zhang MH, Ji M, Gao JD. et al. Research progress on anti-fibrotic mechanism of traditional Chinese medicine polysaccharides. Chin Herb Med 2024; 55 (04) 1063-1074
• 44 Liu MH, Lin AH, Ko HK, Perng DW, Lee TS, Kou YR. Prevention of bleomycin-induced pulmonary inflammation and fibrosis in mice by paeonol. Front Physiol 2017; 8: 193
• 45 Zhang F, Jiang J, Sun Y. et al. Novel paeonol derivatives: Design, synthesis, and their activity in relieving idiopathic pulmonary fibrosis via the PIM1/p65 pathway. Bioorg Chem 2025; 163: 108731
• 46 de Miguel-Díez J, Suárez-Llanos JP, Figueira-Gonçalves JM. et al. SEPAR and SEEN consensus document on nutritional assessment and management in patients with COPD. Arch Bronconeumol 2025; S0300-2896 (25)00307-2
• 47 Kahriman B, Satici C. Beyond emphysema: unraveling reversibility and inflammatory profiles in mild to moderate COPD. Chest 2025; 168 (03) e86-e87
• 48 Li M, Wang Y, Chen Y. et al. A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula. Pharmacol Ther 2024; 264: 108728
• 49 Ma J, Liu X, Wei Y. et al. Effective component compatibility of Bufei Yishen Formula III which regulates the mucus hypersecretion of COPD rats via the miR-146a-5p/EGFR/MEK/ERK Pathway. Evid Based Complement Alternat Med 2022; 2022: 9423435
• 50 Li J, Zhao P, Tian Y. et al. The anti-Inflammatory effect of a combination of five compounds from five Chinese herbal medicines used in the treatment of COPD. Front Pharmacol 2021; 12: 709702
• 51 Qin Y, Li M, Tian Y. et al. Compatibility characteristics of Bufei Yishen formula III in regulating chronic obstructive pulmonary disease mucus hypersecretion. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2021; 33 (11) 1309-1314
• 52 Xu K, Shao X, Lu R. et al. Effective-component compatibility of Bufei Yishen Formula III protects lung air-blood barrier by regulating the oxidative stress: via the nuclear factor-E(2)-related factor 2 pathway. Int J Chron Obstruct Pulmon Dis 2025; 20: 2211-2226
• 53 Li Y, Juergens RA, Finley C, Swaminath A. Current and future treatment options in the management of stage III NSCLC. J Thorac Oncol 2023; 18 (11) 1478-1491
• 54 Gebru MT, Hoffman TE, Boudreau A. et al. Loss of UXS1 selectively depletes pyrimidines and induces replication stress in KEAP1-mutant lung cancer. Cancer Res 2025; 1-32
• 55 Cai J, Chen Y, Wang K. et al. Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer. BMC Complement Med Ther 2023; 23 (01) 158
• 56 Lv J, Zhu S, Chen H. et al. Paeonol inhibits human lung cancer cell viability and metastasis in vitro via miR-126-5p/ZEB2 axis. Drug Dev Res 2022; 83 (02) 432-446
• 57 Zhang L, Chen WX, Li LL. et al. Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3/NF-κB signaling. Front Pharmacol 2020; 11: 572616
• 58 Li M, Cai O, Yu Y, Tan S. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis. Phytomedicine 2022; 96: 153903
• 59 Ruan H, Long M, Li J, Zhang D, Feng N, Zhang Y. Sustained-release hydrogen-powered bilateral microneedles integrating CD-MOFs for in situ treating allergic rhinitis. Adv Healthc Mater 2024; 13 (22) e2400637
• 60 Li H, Zhu J, Wang C. et al. Paeonol loaded cyclodextrin metal-organic framework particles for treatment of acute lung injury via inhalation. Int J Pharm 2020; 587: 119649
• 61 Ma C, Miao QL, Song XB. et al. Paeonol potentiates colistin efficacy against K. pneumoniae by promoting membrane disruption and oxidative damage. Phytomedicine 2024; 135: 156061
• 62 Zhang CM, Guo YG, Sun XQ. et al. Study on in vitro antibacterial activity of 18 Chinese herbal water decoctions and their extract concentrated powders against mink-derived Klebsiella pneumoniae. Heilongjiang Anim Sci Vet Med 2019; [phone]
• 63 Chen KH, Xu R, Ye HJ. et al. Evaluating the efficacy and safety of emodin, luteolin, and paeonol combination from Dahuang Mudan decoction in ameliorating ulcerative colitis. J Ethnopharmacol 2025; 346: 119692
• 64 Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol 2023; 20 (01) 33-48
• 65 Zhang Y, Xu L, Qiu SH. et al. Research on preparation of β-cyclodextrin nanosponge and paeonolloading effects. Shipin Anquan Zhiliang Jiance Xuebao 2025; 16 (11) 215-221
• 66 Xu HT, Liao HZ, Zhou JY. et al. Preparation, characterization and performance evaluation of nanofibermembranes loaded with paeonol. Chin Tradit Herbal Drugs 2023; 54 (14) 4493-4500
• 67 Wang Y, Li BS, Zhang ZH. et al. Paeonol repurposing for cancer therapy: From mechanism to clinical translation. Biomed Pharmacother 2023; 165: 115277
• 68 Zhao JN, Chen CY, Hua H. et al. A new interpretation of the complex pharmacology of traditional Chinese medicine: as an ideal form of the effective substances of traditional Chinesemedicine, the formula-derived nanoparticles (FDN) can achieve multi-levelthree-dimensional targeted regulation of the dynamic disease network. Chin J Chin Mater Med. 2025; 50 (19) 5305-5322
• 69 Sobol Ż, Chiczewski R, Wątróbska-Świetlikowska D. Advances in liposomal drug delivery: multidirectional perspectives on overcoming biological barriers. Pharmaceutics 2025; 17 (07) 885
• 70 Wang Y, Yue Y, Jia R. et al. Design and evaluation of paeonol-loaded liposomes in thermoreversible gels for atopic dermatitis. Gels 2023; 9 (03) 198
• 71 Chen WY, Chen XL, Dong NN. et al. Preparation of essential components of Gleditsiae Fructus Abnormalis liposome and evaluation on in vitro release and blood -brain barrier penetration. J Lishizhen Tradit Chin Med 2025; 36 (22) 4272-4280